pp-119 Tablets, film coated

"Indication: Immune-mediated inflammatory diseases, including hidradenitis suppurativa (HS) and other conditions driven by dysregulated innate immune signaling; focus on patients with moderate-to-severe disease inadequately controlled by standard therapies Clinical stage: Phase 1b clinical development (ongoing), with Phase 2 planned Modality: Small molecule Mechanism / Target: Selective RIPK2 (Receptor-interacting serine/threonine-protein kinase 2) inhibitor, blocking NOD1/NOD2 signaling pathways and downstream NF-κB–mediated inflammatory cytokine production Route / form: Oral Differentiation: Oral, targeted inhibition of RIPK2 offers a novel mechanism to modulate innate immune signaling upstream of multiple inflammatory pathways; potential for improved safety versus broad immunosuppressants and applicability across multiple inflammatory indications; positioned as a first-in-class approach in diseases like hidradenitis suppurativa